Ryvu Therapeutics S.A. 9Y4.F Stock
Ryvu Therapeutics S.A. Price Chart
Ryvu Therapeutics S.A. 9Y4.F Financial and Trading Overview
| Ryvu Therapeutics S.A. stock price | 12.5 EUR |
| Previous Close | 12.94 EUR |
| Open | 13.22 EUR |
| Bid | 13.42 EUR x N/A |
| Ask | 14.18 EUR x N/A |
| Day's Range | 13.22 - 13.22 EUR |
| 52 Week Range | 4.88 - 13.54 EUR |
| Volume | 200 EUR |
| Avg. Volume | 3 EUR |
| Market Cap | 305.65M EUR |
| Beta (5Y Monthly) | 0.59452 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
9Y4.F Valuation Measures
| Enterprise Value | 313.05M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Ryvu Therapeutics S.A. Stock Price History
| Beta (5Y Monthly) | 0.59452 |
| 52-Week Change | 151.20% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 13.54 EUR |
| 52 Week Low | 4.88 EUR |
| 50-Day Moving Average | 12.08 EUR |
| 200-Day Moving Average | 10.44 EUR |
9Y4.F Share Statistics
| Avg. Volume (3 month) | 3 EUR |
| Avg. Daily Volume (10-Days) | 20 EUR |
| Shares Outstanding | 23.12M |
| Float | 13.68M |
| Short Ratio | N/A |
| % Held by Insiders | 37.49% |
| % Held by Institutions | 39.21% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -93.59% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 76.98% |
| EBITDA Margin | -62.88% |
Management Effectiveness
| Return on Assets (ttm) | -11.76% |
| Return on Equity (ttm) | -31.19% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | 169.90% |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | -0.94 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | 3.91 EUR |
| Current Ratio (mrq) | 9.103 |
| Book Value Per Share (mrq) | N/A |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Ryvu Therapeutics S.A.
| Country | Germany |
| State | N/A |
| City | Kraków |
| Address | Leona Henryka Sternbacha 2 |
| ZIP | 30-394 |
| Phone | 48 12 314 0200 |
| Website | https://www.ryvu.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 217 |
Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Q&A For Ryvu Therapeutics S.A. Stock
What is a current 9Y4.F stock price?
Ryvu Therapeutics S.A. 9Y4.F stock price today per share is 12.5 EUR.
How to purchase Ryvu Therapeutics S.A. stock?
You can buy 9Y4.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ryvu Therapeutics S.A.?
The stock symbol or ticker of Ryvu Therapeutics S.A. is 9Y4.F.
Which industry does the Ryvu Therapeutics S.A. company belong to?
The Ryvu Therapeutics S.A. industry is Biotechnology.
How many shares does Ryvu Therapeutics S.A. have in circulation?
The max supply of Ryvu Therapeutics S.A. shares is 23.15M.
What is Ryvu Therapeutics S.A. Price to Earnings Ratio (PE Ratio)?
Ryvu Therapeutics S.A. PE Ratio is now.
What was Ryvu Therapeutics S.A. earnings per share over the trailing 12 months (TTM)?
Ryvu Therapeutics S.A. EPS is -0.94 EUR over the trailing 12 months.
Which sector does the Ryvu Therapeutics S.A. company belong to?
The Ryvu Therapeutics S.A. sector is Healthcare.